The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Johnson & Johnson (NYSE:JNJ) is among the stocks on Jim Cramer’s game plan as he shared his take on the market post Iran-U.S. ceasefire talks. Cramer noted that it has become his favorite drug stock instead of Eli Lilly, as he said:

Now, my favorite drug stock reports next week, too, and that’s not Lilly anymore. It’s Johnson & Johnson. We own this one for the Charitable Trust, and I think we’re going to hear that it has the most blockbusters and the best pipeline in the industry. This is a company transformed, shedding slower, growing divisions, focusing on research that can produce lifesaving drugs. I eagerly await this one. Now, word to the wise, it’s really important. JNJ has a habit of getting hammered on the news release when it comes out in the morning, okay, and then rallying, once the conference call starts. If it gets blasted, try to get some.

Photo by Adam Nowakowski on Unsplash

Johnson & Johnson (NYSE:JNJ) develops and sells healthcare products, including pharmaceuticals and medical technologies, with treatments in immunology, oncology, neuroscience, cardiovascular care, and infectious diseases.

While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.